Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.3 USD | +8.33% | -5.11% | +223.38% |
Business Summary
Number of employees: 118
Sales per Business
USD in Million | 2023 | Weight | Delta |
---|---|---|---|
Precision-targeted Alpha Therapies
100.0
%
| 1 | 100.0 % | - |
Sales per region
USD in Million | 2023 | Weight | Delta |
---|---|---|---|
United States
100.0
%
| 1 | 100.0 % | - |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Johan Spoor
CEO | Chief Executive Officer | 52 | 23-02-02 |
Mark Austin
DFI | Director of Finance/CFO | 37 | 17-06-30 |
Jonathan Hunt
DFI | Director of Finance/CFO | 57 | 23-02-02 |
Markus Puhlmann
CTO | Chief Tech/Sci/R&D Officer | - | - |
Andrew Bright
PRN | Corporate Officer/Principal | - | 23-04-02 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Heidi Henson
BRD | Director/Board Member | 58 | 23-05-31 |
Lori Woods
CHM | Chairman | 61 | 23-02-02 |
Director/Board Member | 58 | 23-02-02 | |
Johan Spoor
CEO | Chief Executive Officer | 52 | 23-02-02 |
Frank Morich
BRD | Director/Board Member | 69 | 23-02-02 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 638,431,857 | 500,823,207 ( 78.45 %) | 0 | 78.45 % |
Company contact information
Perspective Therapeutics, Inc.
2401 Elliott Avenue Suite 320
98121, Seattle
+
http://perspectivetherapeutics.comSector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+223.38% | 809M | |
+49.67% | 57.87B | |
+41.65% | 40.25B | |
-6.84% | 39.94B | |
-5.96% | 28.54B | |
+12.97% | 26.4B | |
-19.86% | 19.33B | |
+32.36% | 12.4B | |
+0.34% | 12.23B | |
+25.44% | 12.2B |
- Stock Market
- Equities
- CATX Stock
- Company Perspective Therapeutics, Inc.